铽-161与生长抑素受体拮抗剂联合用于神经内分泌肿瘤治疗的潜在范式转变
该临床前研究比较了发射β¯及转换/Auger电子的铽-161与镥-177分别标记生长抑素受体激动剂(DOTATOC、DOTATOC-NLS)和拮抗剂(DOTA-LM3)对神经内分泌肿瘤细胞及荷瘤小鼠的疗效。体外显示[161Tb]Tb-DOTA-LM3抑制细胞活力比[177Lu]Lu-DOTA-LM3强102倍,而铽-161标记的激动剂仅比镥-177标记物强4-5倍;体内证实[161Tb]Tb-DOTA-LM3显著延迟肿瘤生长并延长小鼠生存。结论提示基于临床前数据,[161Tb]Tb-DOTA-LM3可能优于临床使用的[177Lu]Lu-DOTATOC。
要点
- 膜定位的SSTR拮抗剂DOTA-LM3与铽-161短程电子结合获益明显。
- 体外[161Tb]Tb-DOTA-LM3比[177Lu]Lu-DOTA-LM3强102倍。
- 体内[161Tb]Tb-DOTA-LM3显著延迟肿瘤生长并延长小鼠生存。
核心结论
- 使用膜定位的DOTA-LM3可从铽-161发射的短程电子中获益。
- 基于临床前数据,[161Tb]Tb-DOTA-LM3可能优于临床使用的[177Lu]Lu-DOTATOC治疗神经内分泌肿瘤患者。
研究设计与样本
- 体外研究比较铽-161与镥-177标记的生长抑素类似物降低SSTR阳性AR42J肿瘤细胞活力和存活的能力。
- 在荷瘤小鼠中评估放射肽的组织分布,并用DOTATOC或DOTA-LM3分别开展铽-161与镥-177疗效比较的小鼠治疗研究。
主要发现
- 体外[161Tb]Tb-DOTA-LM3抑制肿瘤细胞活力的效力比[177Lu]Lu-DOTA-LM3强102倍。
- 铽-161标记的DOTATOC和DOTATOC-NLS抑制肿瘤细胞活力仅比其镥-177标记 counterparts 强4-5倍。
- 体内[161Tb]Tb-DOTA-LM3在延迟肿瘤生长方面显著优于[177Lu]Lu-DOTA-LM3,并延长小鼠生存。
- 与DOTATOC联用时铽-161相比镥-177也表现出治疗优势。
- 核定位序列(NLS)损害DOTATOC-NLS的体内组织分布,故未用于治疗。
关键数值与推荐
- 体外[161Tb]Tb-DOTA-LM3比[177Lu]Lu-DOTA-LM3强102倍。
- 铽-161标记的DOTATOC和DOTATOC-NLS比镥-177标记物强4-5倍。
临床怎么用
- 临床前数据支持进一步评估[161Tb]Tb-DOTA-LM3用于神经内分泌肿瘤治疗。
- 膜定位SSTR拮抗剂与短程电子发射核素联用可能增强疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The β¯-emitting terbium-161 also emits conversion and Auger electrons, which are believed to be effective in killing single cancer cells. Terbium-161 was applied with somatostatin receptor (SSTR) agonists that localize in the cytoplasm (DOTATOC) and cellular nucleus (DOTATOC-NLS) or with a SSTR antagonist that localizes at the cell membrane (DOTA-LM3). The aim was to identify the most favorable peptide/terbium-161 combination for the treatment of neuroendocrine neoplasms (NENs). METHODS: The capability of the 161Tb- and 177Lu-labeled somatostatin (SST) analogues to reduce viability and survival of SSTR-positive AR42J tumor cells was investigated in vitro. The radiopeptides' tissue distribution profiles were assessed in tumor-bearing mice. The efficacy of terbium-161 compared to lutetium-177 was investigated in therapy studies in mice using DOTATOC or DOTA-LM3, respectively. RESULTS: In vitro, [161Tb]Tb-DOTA-LM3 was 102-fold more potent than [177Lu]Lu-DOTA-LM3; however, 161Tb-labeled DOTATOC and DOTATOC-NLS were only 4- to fivefold more effective inhibiting tumor cell viability than their 177Lu-labeled counterparts. This result was confirmed in vivo and demonstrated that [161Tb]Tb-DOTA-LM3 was significantly more effective in delaying tumor growth than [177Lu]Lu-DOTA-LM3, thereby, prolonging survival of the mice. A therapeutic advantage of terbium-161 over lutetium-177 was also manifest when applied with DOTATOC. Since the nuclear localizing sequence (NLS) compromised the in vivo tissue distribution of DOTATOC-NLS, it was not used for therapy. CONCLUSION: The use of membrane-localizing DOTA-LM3 was beneficial and profited from the short-ranged electrons emitted by terbium-161. Based on these preclinical data, [161Tb]Tb-DOTA-LM3 may outperform the clinically employed [177Lu]Lu-DOTATOC for the treatment of patients with NENs.
引用
- Borgna F, Haller S, Rodriguez JMM, et al. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2021. PMID: 34625828. doi:10.1007/s00259-021-05564-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。